Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT05692635 Recruiting - Brain Metastases Clinical Trials

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Start date: August 30, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.

NCT ID: NCT05689619 Recruiting - Breast Cancer Clinical Trials

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

SILMET
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

NCT ID: NCT05689112 Recruiting - Tumor, Brain Clinical Trials

Microscopy Imaging of Whole-mount Stained Human Tissues

Start date: January 10, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this clinical trial is to develop an imaging platform for intraoperative tumor margin delineation in 250 cases of tumor-suffered patients. The main questions it aims to answer are: • to develop the protocol of rapid assessment of surgical specimens without need for fixation, embedding, and cryosectioning required for conventional histopathology. Participants will provide a small piece of their surgical specimens from tumor removal surgery . If there is a comparison group: Researchers will compare normal specimens to see if we can observe the difference.

NCT ID: NCT05686798 Recruiting - Glioblastoma Clinical Trials

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Start date: November 29, 2022
Phase: Phase 1
Study type: Interventional

The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

NCT ID: NCT05679089 Recruiting - Intracranial Tumors Clinical Trials

AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors

ASCEND-BRAIN
Start date: November 1, 2022
Phase:
Study type: Observational

ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.

NCT ID: NCT05673928 Recruiting - Brain Metastases Clinical Trials

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Start date: May 16, 2023
Phase: Phase 2
Study type: Interventional

To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

NCT ID: NCT05672043 Recruiting - Glioma Clinical Trials

Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China

GRIPP
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.

NCT ID: NCT05669352 Recruiting - Clinical trials for Melanoma Metastatic in the Brain

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Start date: July 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). The investigators hypothesize that the addition of CA-4948 will reduce the rate of distant intracranial failure and reduce the need for subsequent radiation therapy. The investigators also propose that it will have a significant reduction in radiation necrosis and improve patient-reported symptoms and quality of life. This trial represents the first time an oral IRAK-4 inhibitor has been used in combination with aPD1 therapy in MBM and will yield valuable insight into its synergistic potential both in MBM and additional sites of metastases.

NCT ID: NCT05660499 Recruiting - Primary Brain Tumor Clinical Trials

Impact of the Development of Pediatric Palliative Care

PTB
Start date: February 15, 2021
Phase:
Study type: Observational

Despite medical advances, cancer remains the leading cause of death by disease in children. Brain tumors are the second most common cause of cancer in children after leukemia, representing 25% of pediatric cancers. The overall survival rate is about 50% with extremes ranging from less than 5% to more than 90% depending on the histological type of brain tumor. The end of life of children with a brain tumor is marked by the possibility of discomfort symptoms, painful or not, and by a progressive neurological deterioration, which makes the management of these children complex for both families and health professionals. Over the last decade, the concept of palliative care has been increasingly integrated into pediatric onco-hematology services with the primary objective of better symptom control in a global approach to the child and his or her family in order to aim at a better quality of life.

NCT ID: NCT05638425 Recruiting - Brain Metastases Clinical Trials

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Start date: December 31, 2021
Phase:
Study type: Observational

This is a prospective, single-center observational clinical study aimed at the efficacy and safety of radiotherapy combined with PD-1 inhibitors and chemotherapy in the treatment of Chinese patients with symptomatic NSCLC with brain metastases.